Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
about
L-carnitine for cognitive enhancement in people without cognitive impairmentPrescription stimulant medication misuse: Where are we and where do we go from here?L-carnitine for cognitive enhancement in people without cognitive impairment.Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate.
P2860
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@en
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@nl
type
label
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@en
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@nl
prefLabel
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@en
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland.
@nl
P2860
P50
P356
P1476
Use of neuroenhancement drugs: prevalence, frequency and use expectations in Switzerland
@en
P2093
Meichun Mohler-Kuo
Stéphane Deline
P2860
P304
P356
10.3390/IJERPH110303032
P50
P577
2014-03-12T00:00:00Z